Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab with Carboplatin-Paclitaxel in Thymic Carcinoma
NCT03694002Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in thymic carcinoma (TC), sponsored by SWOG Cancer Research Network. Started Mar 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT03694002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694002.